Overview

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Zhejiang University
Collaborator:
Yake Biotechnology Ltd.
Treatments:
Carbamide Peroxide